Anti-MYO3A monoclonal antibody
Pre-made anti-MYO3A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to MYO3A/MYO3A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP2616-Ab-1/ GM-Tg-hg-IP2616-Ab-2 | Anti-Human MYO3A monoclonal antibody | Human |
GM-Tg-rg-IP2616-Ab-1/ GM-Tg-rg-IP2616-Ab-2 | Anti-Rat MYO3A monoclonal antibody | Rat |
GM-Tg-mg-IP2616-Ab-1/ GM-Tg-mg-IP2616-Ab-2 | Anti-Mouse MYO3A monoclonal antibody | Mouse |
GM-Tg-cynog-IP2616-Ab-1/ GM-Tg-cynog-IP2616-Ab-2 | Anti-Cynomolgus/ Rhesus macaque MYO3A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP2616-Ab-1/ GM-Tg-felg-IP2616-Ab-2 | Anti-Feline MYO3A monoclonal antibody | Feline |
GM-Tg-cang-IP2616-Ab-1/ GM-Tg-cang-IP2616-Ab-2 | Anti-Canine MYO3A monoclonal antibody | Canine |
GM-Tg-bovg-IP2616-Ab-1/ GM-Tg-bovg-IP2616-Ab-2 | Anti-Bovine MYO3A monoclonal antibody | Bovine |
GM-Tg-equg-IP2616-Ab-1/ GM-Tg-equg-IP2616-Ab-2 | Anti-Equine MYO3A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP2616-Ab-1/ GM-Tg-hg-IP2616-Ab-2; GM-Tg-rg-IP2616-Ab-1/ GM-Tg-rg-IP2616-Ab-2; GM-Tg-mg-IP2616-Ab-1/ GM-Tg-mg-IP2616-Ab-2; GM-Tg-cynog-IP2616-Ab-1/ GM-Tg-cynog-IP2616-Ab-2; GM-Tg-felg-IP2616-Ab-1/ GM-Tg-felg-IP2616-Ab-2; GM-Tg-cang-IP2616-Ab-1/ GM-Tg-cang-IP2616-Ab-2; GM-Tg-bovg-IP2616-Ab-1/ GM-Tg-bovg-IP2616-Ab-2; GM-Tg-equg-IP2616-Ab-1/ GM-Tg-equg-IP2616-Ab-2 |
Products Name | Anti-MYO3A monoclonal antibody |
Format | mab |
Target Name | MYO3A |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-MYO3A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP2616-Ag-1 | Recombinant multi-species MYO3A/ DFNB30 protein |
Target information
Target ID | GM-IP2616 |
Target Name | MYO3A |
Gene ID | 53904,667663,498806,707165,487106,101086983,535824,100055461 |
Gene Symbol and Synonyms | 9030416P08Rik,DFNB30,MYO3A |
Uniprot Accession | Q8NEV4 |
Uniprot Entry Name | MYO3A_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000095777 |
Target Classification | Kinase |
The target: MYO3A, gene name: MYO3A, also named as DFNB30. The protein encoded by this gene belongs to the myosin superfamily. Myosins are actin-dependent motor proteins and are categorized into conventional myosins (class II) and unconventional myosins (classes I and III through XV) based on their variable C-terminal cargo-binding domains. Class III myosins, such as this one, have a kinase domain N-terminal to the conserved N-terminal motor domains and are expressed in photoreceptors. The protein encoded by this gene plays an important role in hearing in humans. Three different recessive, loss of function mutations in the encoded protein have been shown to cause nonsyndromic progressive hearing loss. Expression of this gene is highly restricted, with the strongest expression in retina and cochlea. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.